Business Wire

Xpeng P7 Launches in China

Share

Xpeng Motors, a leading Chinese electric vehicle and technology company, today announced the launch of its P7 super-long range, high-performance, fast-charging intelligent EV sports sedan, its second production model. The P7 is immediately available for order in China, in 3 versions and 8 configurations, and customer deliveries will commence end June 2020, starting at RMB 229,900 – 349,900 (US$32,462 – 49,404) post subsidies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200427005378/en/

Xpeng P7 super-long range smart sedan (Photo: Business Wire)

Xpeng P7 super-long range smart sedan (Photo: Business Wire)

“Today is a milestone in the 5-year history of Xpeng Motors,” said He Xiaopeng, Chairman & CEO. “The P7’s launch solidifies Xpeng Motors’ leading position in China’s smart EV market. Our ability to launch the P7 in the challenging conditions of the COVID-19 crisis is a testament to the strength of our young company.”

With superior autonomy and connectivity, the Xpeng P7 incorporates many breakthroughs and firsts. It is the first L3 autonomy-ready production vehicle in the Chinese market. It boasts world-beating NEDC 706km super-long driving range and 4.3s 1-100km/h acceleration in some configurations. It is the first production model in any market worldwide powered by NVIDIA’s DRIVE AGX Xavier system-on-a-chip, delivering 30 TOPS (trillions of operations per second) performance while consuming only 30 watts of power.

Strong performance against key industry benchmarks

  • High-performance 3-in-1 electric drive system – compact, light, efficient, reliable – with world-class motor energy density of 2.0 kW/kg and an efficiency up to 97.5%.
  • Longest-driving range EV in China at NEDC 706km.
  • World’s first EV with Infineon 950 IGBT module, delivering up to 580A to motor for continuous 40s.
  • German luxury sports style auto brand joint-developed chassis, optimized suspension & layout.
  • Bosch / Brembo braking system, new-gen Bosch iBooster braking recycling, c.100% energy recovery, with 35m 100km/h brake distance.
  • Autonomous driving system XPILOT3.0 for China’s challenging roads - 12 ultrasonic sensors, 5 millimeter-wave radars, 14 cameras –industry’s only 360° multi-perception integrated system.
  • Qualcomm Snapdragon 820 high-performance auto chip running Xpeng Xmart OS 2.0 - world’s first intelligent full-scenario voice interactive system, integrating App stores and Alipay mini-program dual ecosystem.
  • Whole-car OTA upgrade capability for in-car apps as well as ECU-controlled functions, supported by its SEPA (Smart Electric Platform Architecture).
  • CATL high-density slim-profile prismatic battery pack, 110mm height, 80.9kWh with energy density reaching 170Wh/kg.
  • Fast charging: from 30% to 80% charge as fast as 28 mins, 120km range in 10 mins; with China’s first remote-controlled concealed charging plug.
  • 5-level safety design: Passive, battery, active, air quality and data security measures.

Market-leading autonomous driving architecture

The Xpeng P7 has the strongest autonomous driving architecture among production vehicles in China. Powered by NVIDIA's DRIVE Xavier, the P7 operates both the XPILOT3.0 and XPILOT2.0 systems concurrently to provide complete redundancy. The XPILOT3.0 reaches high levels of Functional Safety to offer guaranteed stability and security. As the foundation of the Xpeng P7s technology, the safety framework is designed and benchmarked to C-NCAP 5-star standards.

The P7’s multiple front-facing, side and rear-facing cameras cover a 180°-degree+ field of view, following tight curves and recognizing vehicles cutting in at close quarters. The P7 is equipped with the industry’s first new-generation forward-looking millimeter wave radar sensors, with detection distance over 200 meters, offering market-leading accuracy and angle of view, effectively penetrating rain, fog, haze to perceive surroundings in reduced visibility conditions. Four more high-performance millimeter wave radars are positioned at each corner of the P7 – an industry-leading configuration.

The P7’s lane-level positioning function is backed by AutoNavi’s high-definition high-precision maps with high-level accuracy. The GPS/RTK/IMU positioning hardware allows positioning accuracy to the centimeter level, or less than 0.3% thanks to real-time positioning map construction technology (SLAM). These complementary features effectively enhance the stability and safety of the P7’s autonomous driving function on overpasses, in tunnels or under bad weather conditions. Coupled with the precise control capabilities brought by Bosch iBooster, the P7 performs a suite of advanced ADAS functions, including navigation-guided pilot (NGP) for highways, traffic light recognition assistance and the first production model to feature memory parking for car parks.

Superior style and support

As well as high technology, the P7 boasts superior styling and ergonomic features designed to enrich and enhance the driving experience. The bodywork is crafted with an elegant minimalist profile that lowers air resistance to a market-leading Cd0.236, delivering longer range and a quieter, smoother ride.

The intelligent cockpit is designed to interact with driver and passengers through voice commands, infotainment, and a concert hall-standard 600w Dynaudio surround-sound audio environment. A panoramic glass roof, frameless doors, and a low-profile console offer wide-angle views in all directions. Nappa leather styling is available for that extra touch of luxury.

The P7 will be available through Xpeng’s growing sales network, already some 113 outlets across 57 cities, and its service network of 73 stores in 52 cities. Supercharging stations for the P7 have already reached 164 contracted and signed units across 35 cities, while its supporting 3rd-party charging pile networks number some 200,000+ units across China.

“Our philosophy of end-to-end closed-loop R&D is what sets us apart among China’s intelligent EV manufacturers,” Chairman He concluded. “Regular OTA upgrades will ensure that the P7 continues to grow and improve as we do.”

The Xpeng P7 is immediately available in China in various configurations, starting from RMB 229,900 – 349,900 (US$32,462 – 49,404) post subsidies.

4WD High Performance (4.3s 0-100km/h acceleration): RMB 339,900 – 349,900
RWD Super-Long Range: (656km – 706km NEDC): RMB 254,900 – 276,900
RWD Long Range (568km NEDC) RMB 229,900 – 259,900
(All post subsidies)

For Xpeng P7’s videos and images please visit : https://183.236.41.237
Log-in name: xpfilelv2
Password: xpfile@P7@

About XPENG Motors

Xpeng Motors is a leading Chinese electric vehicle company that designs and manufactures automobiles that are seamlessly integrated with the Internet and utilize the latest advances in artificial intelligence. The company's initial backers include its Chairman & CEO, He Xiaopeng, who’s also the co-founder of UCWeb Inc. and a former Alibaba executive. Established in 2014, Xpeng Motors has a senior management team with diverse backgrounds, including Co-founders Henry Xia and He Tao, both former senior executives at Guangzhou Auto with expertise in innovative automotive technology and R&D, and Vice Chairman & President Brian Gu, former Chairman of Asia Pacific Investment Banking at J.P. Morgan. It has received funding from strategic investors Alibaba Group and Xiaomi Corporation, as well as other prominent Chinese and international investors including IDG Capital, Morningside Venture Capital, GGV Capital and Primavera Capital. The company launched its first production model, the G3 SUV, in Dec 2018, and will launch its second production model, the P7 electric sports sedan, in April 2020 with deliveries to Chinese customers in Q2 2020. Xpeng Motors is headquartered in Guangzhou, China with offices in Beijing, Shanghai, Silicon Valley and San Diego in the U.S. and manufacture centers in Zhengzhou and Zhaoqing. For more information, please visit the official website: https://en.xiaopeng.com/

Follow us on social media for latest Xpeng news:
FacebookTwitterLinkedInYouTubeInstagram

Contact information

For further information, please contact Marie Cheung:
Email: mariecheung@xiaopeng.com
Mobile: (+852) 9750 5170 / (+86) 1550 7577 546

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Citi Private Bank Issues Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World4.12.2020 17:36:00 CETPress release

Citi Private Bank has released its Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World. The twice-yearly publication provides in-depth insights into the global economy and financial markets for the coming year and highlights multi-year “unstoppable trends” for client portfolios. This edition outlines why this is a remarkable time to be an investor. Just as the pandemic changed the price of every security when it arrived, the departure of COVID will mark the beginning of a new economic cycle, creating new opportunities for investors. Citi Private Bank expects 2021 will benefit from an economy that demonstrated resilience in the face of the worst global healthcare crisis in more than a century. 2020 was an opportunity for the world to “test drive the future” and make way for growth as the pandemic ebbs. The tailwinds for 2021 are underappreciated: our financial system is strong, government actions to protect individuals and businesses have been effective, technological

Takashi Nagao Appointed President and Chief Executive Officer of Medicago4.12.2020 17:00:00 CETPress release

Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi Nagao as the company’s new President and Chief Executive Officer. Prior to becoming President and CEO, Mr. Nagao served as the Chairman of the Board of Medicago, where for the last four years, he has guided Medicago executives to get the company to where it is today. Medicago, a research and development company for the last 20 years, is embarking on a transformative year, one that will see the company build on its R&D roots to become a company that also produces and commercializes vaccines and other immunotherapies. Mr. Nagao has extensive experience leading pharmaceutical companies through the pre-commercial and commercial process and is well positioned to ensure the successful launch of Medicago’s COVID-19 and influenza vaccines, subject to regulatory approvals. Mr. Nagao will continue Medicago’s evolution towards its goal of being a fully operational commercial entity, able to respond

WorldRemit Leads the Way Offering a USD Payout Option in Nigeria4.12.2020 16:46:00 CETPress release

WorldRemit, a leading digital cross-border payments business has announced that its customers in Nigeria can now receive remittances in foreign currency (USD) through its cash pick up providers. Following the announcement of the Central Bank of Nigeria (CBN) a day before, WorldRemit quickly adapted to the new requirements making it the first digital service to offer its customers worldwide the option of cash pickup in USD in Nigeria. WorldRemit enables Nigerians in over 50 countries around the world to support their family and friends in Nigeria. The decision by the Central Bank of Nigeria (CBN) to allow international money transfers to be paid in foreign currency, is aimed at providing increased liquidity in the foreign exchange market. The bank explained that the new regulation is part of its efforts to liberalize, simplify and improve the receipt and administration of diaspora remittances into Nigeria. Gbenga Okejimi, Country Manager, Nigeria and Ghana, at WorldRemit, said:“ We are

PPC Upgraded to ‘B’ with ‘Stable’ Outlook by S&P4.12.2020 15:16:00 CETPress release

In its annual research update released on 27 November 2020, S&P upgraded PPC’s stand-alone credit profile (SACP) upward by two notches to ‘B’ from ‘CCC+’, resulting in an overall upgrade of the long-term credit rating of PPC to ‘B’ from ‘B-‘. According to S&P the two notch upgrade in PPC’s standalone corporate rating confirms that the Company’s strategic repositioning and the improved Greek energy market fundamentals have transformed its competitive position, reducing past concerns over its liquidity and long-term sustainability. The ‘Stable’ outlook underscores S&P’s expectation that PPC will continue to deliver on its transformation plan, with solid liquidity and improved margins. PPC’s strategic plan to convert its generation mix toward lower carbon dioxide (CO2) emissions improve its fleet competitiveness and long-term prospects. As mentioned in their report, S&P expects a substantial increase in EBITDA and improvement in credit metrics on the back of higher profitability as PPC ac

Chengdu Launches Online Exhibition of History and Culture to Enhance Cultural Ties With European Countries4.12.2020 13:17:00 CETPress release

The launching ceremony of Chengdu History and Culture Overseas Virtual Exhibition was held by the Chengdu Chronicles Compilation Committee at Chengdu Chronicles Office on 24 November. The event, along with the unveiling ceremony of Chengdu Chronicles Culture Overseas (Europe) Exchange Cooperation, were witnessed by distinguished guests in many European countries including the Netherlands, Germany and Belgium through video and online connections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201204005278/en/ On November 24, Gao Zhigang (center), Director of Chengdu Chronicles Compilation Committee at Chengdu Chronicles Office, and other guests attend the launching ceremony of Chengdu History and Culture Overseas Virtual Exhibition. (Photo: Business Wire) Chengdu History and Culture Overseas Virtual Exhibition will also be launched at major foreign media platforms for audiences all over the world. Gao ZhiGang, Director of Che

New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint4.12.2020 12:00:00 CETPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK-620 (maribavir), in the treatment of transplant recipients with refractory/resistant cytomegalovirus (CMV) infection. The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment (IAT) in transplant recipients with CMV infection refractory or resistant to existing antiviral treatments (i.e., one or a combination of ganciclovir, valganciclovir, foscarnet or cidofovir). The SOLSTICE trial met its primary endpoint, defined as the proportion of patients who achieved confirmed CMV viremia clearance compared to IAT at the end of Study week 8. In addition, the SOLSTICE trial met its key secondary endpoint, defined as achievement of CMV viremia clearance

Janssen Submits Marketing Authorisation Extension to the European Medicines Agency to Register Paliperidone Palmitate 6-Monthly (PP6M) for Treatment of Schizophrenia in Adults4.12.2020 10:01:00 CETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson submitted a Marketing Authorisation Extension Application to the European Medicines Agency (EMA) to register paliperidone palmitate 6-monthly (PP6M) for the maintenance treatment of schizophrenia in adult patients who are clinically stable on paliperidone palmitate 1‑monthly (PP1M)1 or 3-monthly (PP3M)2 injectable products. If approved, this long‑acting injectable will provide adults living with schizophrenia a twice-yearly dosing regimen, the longest dosing interval available for an antipsychotic medication in the European Economic Area.3 “Janssen’s roots in neuroscience began with research and development of novel therapeutic options for schizophrenia, and this filing builds on that 60-year commitment,” said Bill Martin, Global Therapeutic Area Head, Neuroscience, Janssen Research & Development, LLC. “We designed this unique dosing regimen so people with schizophrenia and their healthcare team can focus less on medication inte

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom